Exchange rates and rabeprazole dull Eisai's first half
This article was originally published in Scrip
Global sales of Eisai's top product, the Alzheimer's disease therapy Aricept (donepezil), edged up by 2% to ¥156.0 billion ($1.73 billion) in the first half, despite the effects of the strong yen on sales outside Japan.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.